Randomized human trial · Evidence assessment
What did VITAL find about fish oil and heart events?
VITAL did not establish a reduction in its primary cardiovascular outcome. A positive result for prescription EPA in a different population cannot be assumed to apply to an ordinary fish-oil supplement.
Longevity Lab Report · Assessed · Main study published 2018-11-10
Claim being examined
Taking a daily marine omega-3 supplement prevents major cardiovascular events in adults without prior cardiovascular disease.
This page assesses the named study and relevant context. It is not a complete systematic review or an individual medical assessment.
What the study measured
- Population
- 25,871 US adults: men aged 50+ and women aged 55+, without cardiovascular disease or cancer at enrollment.
- Study design
- Randomized, double-blind, placebo-controlled factorial trial.
- What was tested
- A daily 1 g marine omega-3 capsule providing 460 mg EPA and 380 mg DHA.
- Comparison
- Olive-oil placebo.
- Duration
- Median 5.3 years.
- Measured outcome
- The combined outcome of heart attack, stroke or cardiovascular death.
- Observed result
- 386 versus 419 participants had a primary cardiovascular event. Hazard ratio 0.92 (95% confidence interval 0.80–1.06). Heart attack alone, a secondary endpoint, was lower.
- Safety limits
- No excess serious bleeding was observed in VITAL. That does not establish safety for higher doses or every person.
- Funding and disclosures
- Supported by NIH grants, with study capsules supplied by manufacturers; see the paper disclosures.
What limits the conclusion?
- The primary and secondary outcomes answer different questions.
- Participants, formulations and comparators differed across the major trials.
Prior and related evidence
REDUCE-IT tested prescription icosapent ethyl in 8,179 statin-treated, higher-risk patients and reduced its primary event composite (17.2% versus 22.0%). The later STRENGTH trial tested a high-dose EPA/DHA formulation in 13,078 high-risk patients and found no significant event reduction.
The source list below distinguishes the main study from context.
What this evidence added
VITAL supplied direct randomized evidence about primary prevention. Later STRENGTH results show that a higher gram dose alone does not reproduce REDUCE-IT.
What it did not establish
These trials do not make different omega-3 products interchangeable. This page does not recommend a product or dose.
Still unknown
- Why results differ across formulations and trials.
- Whether a particular person would benefit: these group averages cannot answer that.
Does this study address your question?
Optionally compare the population, intervention and outcome. These are study comparisons, not medical advice or a treatment recommendation. Your answers stay on this page and are not saved or included in sharing.
Keep the evidence available
Open the public card to print or shareSaved in this browser only. No account or email required.
Assessment history
Sources
- VITAL (Manson et al., 2019)
Main study · Published 2018-11-10 · Checked 2026-11-15 · DOI 10.1056/NEJMoa1811403
Primary publication abstract and indexed results
- REDUCE-IT (Bhatt et al., 2019)
Context · Published 2018-11-10 · Checked 2026-11-15 · DOI 10.1056/NEJMoa1812792
Primary publication abstract and indexed results
- STRENGTH (Nicholls et al., 2020)
Context · Published 2020-11-15 · Checked 2026-11-15 · PMID 33190147
Full primary publication via indexed PMC text
Follow the research in the newsletter
Read the week’s longevity reporting and evidence assessments. Your watchlist and comparison answers are separate from your subscription.
Free. Unsubscribe anytime.
Every grade follows a published rubric. Sponsors do not influence findings or grades.